Introduction
It has recently been suggested that treatment of diabetic patients with sulphonylureas may be associated with an increased mortality from cardiovascular disease (University Group Diabetes Program, 1970) . The only other satisfactory oral antidiabetic agents available at the present time are the diguanides. The mode of action of the diguanides remains uncertain, although their effectiveness in controlling maturity-onset diabetes mellitus and in promoting weight loss in obese diabetic patients is well documented (Hooper, 1967; Clarke & Duncan, 1968 ).
Czyzyk and co-workers (Czyzyk et al., 1968) found that treatment with phenformin caused an improvement in the oral glucose tolerance of diabetic patients but had no effect on the intravenous (i.v.) glucose tolerance. They concluded that phenformin decreases intestinal absorption of glucose. They were uncertain, however, to what extent this effect contributes to the therapeutic action of phenformin. Other workers have also reported that diguanides reduce intestinal absorption of glucose (Mainguet et al., 1970) and may also impair xylose absorption (Berchtold et al., 1969) in diabetic patients.
The present study was carried out to determine the extent to which the hypoglycaemic action of metformin is dependent on glucose malabsorption. Blood glucose levels were measured and i.v. glucose tolerance tests performed after an overnight fast in a further thirteen overweight diabetic patients aged 29-73 years who had previously been treated by diet alone. These measurements were repeated after 1-2 weeks' treatment with metformin 1-5-3-0 g daily in divided doses. The i.v. glucose tolerance tests were carried out using D-glucose 25 g in 50%°solution administered rapidly i.v. The rate constant for disappearance of glucose from blood (K value) was calculated over the next hour (Conard et al., 1953 Frayn & Adnitt (1971) , and D-glucose by the method of Morley, Dawson & Marks (1968) .
Results
Xylose and 30MG absorption (Fig. 1 difference ±SE +2A4 ±7-9%). There was no significant reduction in excretion of either sugar following metformin treatment.
Fasting blood glucose levels (Fig. 2) Mean fasting blood glucose before treatment was 160 mg/100 ml and after treatment 115 mg/100 ml (mean difference ±SE -45 ±9 mg/100 ml). This decrease was significant (P<0 001).
Intravenous glucose tolerance tests (Fig. 3) Mean K value before treatment was 0 59 min-' and after treatment 0-82 min-' (mean difference ±SE +0-24 ±0 06, P<0 01). Intravenous glucose tolerance improved in twelve out of thirteen patients following metformin treatment. Figure 4 shows the change in K value plotted against the initial K value for each patient. There is no evidence that the improvement in i.v. glucose tolerance is related to the initial severity of the diabetes.
Discussion
Some (Berchtold et al., 1969; Stowers & Bewsher, 1969) but not all (Creutzfeldt, 1969) workers have reported a significant reduction during diguanide treatment of the 5-hr xylose excretion following oral administration. Stowers & Bewsher (1969) , however, found no consistent reduction in the 24-hr xylose excretion. The present results show no reduction in xylose excretion over 24 hr. This suggests that although the diguanides may delay the excretion of xylose, there is no overall reduction in xylose absorption. 30MG excretion following oral administration may be used as an index of intestinal glucose absorption. It is absorbed by the same mechanism as glucose and is not significantly metabolized in man (Fordtran et al., 1962) . We have found no reduction in 30MG excretion during the 24 hr following oral administration in patients treated with metformin and therefore think it unlikely that metformin has an effect on intestinal glucose absorption.
The considerable improvement in i.v. glucose tolerance reported here is in contrast to the results of Czyzyk and co-workers (1968) who found no change in i.v. glucose tolerance in mild diabetic patients treated with phenformin for 3 days. There are several possible explanations for this discrepancy. In the present investigation the duration of treatment was longer. Our patients were also more severely diabetic; the mean initial K value for the subjects in the study of Czyzyk was 0O8 min-' whereas in the present study the mean initial K value was 059 min-' increasing to 0X82 min-' after metformin treatment. This might suggest that the beneficial effect of diguanide treatment on intravenous glucose tolerance is related to the initial severity of the diabetes, especially since these drugs have no effect on the intravenous glucose tolerance of normal individuals (Hollobaugh, Rao & Kruger, 1967 , Lyngs0e & Trap-Jensen, 1969 . We have found no evidence that such a relationship exists (Fig. 4) . The other possible explanation for the difference between the results presented here and those of Czyzyk is that metformin but not phenformin causes an improvement in intravenous glucose tolerance as has been suggested by Bouaziz (1966) .
The improvement in intravenous glucose tolerance and reduction in fasting blood glucose level during metformin treatment cannot readily be explained on the basis of an intestinal effect on glucose absorption. Since we have also been unable to demonstrate any reduction in xylose or 30MG absorption during metformin treatment, it would appear that the hypoglycaemic action of this drug does not depend primarily on an intestinal effect. There are, however, reports of interference with vitamin B12 (Berchtold et al., 1969) and possibly folate absorption (Fearnley, 1969) during treatment with diguanides, and further tests of intestinal absorption are therefore being carried out.
